Magenta therapeutics highlights recent progress and expected timing of 2021 milestones, including four ongoing and planned clinical trials

Cambridge, mass.--(business wire)--magenta therapeutics (nasdaq: mgta), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today highlighted progress across its stem cell mobilization and collection and targeted conditioning programs, and set expectations for 2021. these updates will be discussed during a webcast presentation at the 39th annual j.p. morgan healthcare conferenc
DNTH Ratings Summary
DNTH Quant Ranking